¼¼°èÀÇ Pharma 4.0 ½ÃÀå : ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м®-À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, ±â¼úº°, Áö¿ªº°, Àü¸Á ¹× ¿¹Ãø(2024-2031³â)
Global Pharma 4.0 Market Size, Share & Trends Analysis Report By Type, By Application, By End Use, By Technology, By Regional Outlook and Forecast, 2024 - 2031
»óǰÄÚµå : 1555969
¸®¼­Ä¡»ç : KBV Research
¹ßÇàÀÏ : 2024³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 292 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,600 £Ü 5,223,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,320 £Ü 6,267,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 10¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,048 £Ü 8,775,000
PDF (Corporate User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Pharma 4.0 ½ÃÀå ±Ô¸ð´Â ¿¹Ãø ±â°£ µ¿¾È 18.5%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ½ÃÀå ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 2031³â±îÁö 364¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

COVID-19ÀÇ ¿µÇ⠺м®

ÆÒµ¥¹ÍÀº ±â¾÷ÀÌ Åº·ÂÀûÀÌ°í ¹ÎøÇϰí È¿À²ÀûÀÎ Á¦Á¶ ½Ã½ºÅÛÀÇ Çʿ伺À» ÀνÄÇÏ°í ±Ã±ØÀûÀ¸·Î ÀÌ 4.0 ±â¼úÀÇ Ã¤ÅÃÀ» °¡¼ÓÈ­Çß½À´Ï´Ù. COVID COVID-19 ¹é½Å °³¹ß ¹× Á¦Á¶¿¡ ´ëÇÑ ¾Ð·ÂÀº »ý»ê °øÁ¤¸¦ ÃÖÀûÈ­Çϱâ À§ÇÑ AI, ÀÚµ¿È­ ¹× IoTÀÇ °¡Ä¡¸¦ Áï½Ã ÀÔÁõÇß½À´Ï´Ù. ¿¹Ãø ºÐ¼® ¹× ¿ø°Ý ¸ð´ÏÅ͸µ°ú °°Àº ÀÌ·¯ÇÑ 4.0 µµ±¸´Â Á¦¾à ȸ»ç°¡ È¥¶õÀ» ÃÖ¼ÒÈ­ÇÏ°í ¹Ì·¡ÀÇ À§±â¿¡ ´ëºñÇÏ·Á°í ³ë·ÂÇ߱⠶§¹®¿¡ ³Î¸® °ü½ÉÀ» ²ø¾ú½À´Ï´Ù. ÆÒµ¥¹ÍÀÇ Àå±âÀûÀÎ ¿µÇâÀº Á¦¾à »ê¾÷¿¡¼­ µðÁöÅÐ º¯È­¿¡ ´ëÇÑ °­ÇÑ ÃßÁø·ÂÀÌ µÇ¾ú½À´Ï´Ù. µû¶ó¼­ ÆÒµ¥¹ÍÀº ½ÃÀå¿¡ Àü¹ÝÀûÀ¸·Î ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù.

½ÃÀå ¼ºÀå ¿äÀÎ

¾öû³­ ¾çÀÇ µ¥ÀÌÅ͸¦ ½Ç½Ã°£À¸·Î ó¸®ÇÏ´Â ´É·ÂÀ¸·Î Á¦¾à ȸ»ç´Â ¿¹Ãø À¯Áö º¸¼ö Àü·«À» äÅÃÇÒ ¼ö ÀÖÀ¸¸ç AI ÁÖµµ ºÐ¼®À» ÅëÇØ ÀåºñÀÇ ÀáÀçÀû °íÀåÀ» ½ÇÁ¦·Î ÀÏÀ¸Å°±â ÈξÀ Àü¿¡ °¨ÁöÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ±â´ÉÀº ´Ù¿îŸÀÓÀ» ÃÖ¼ÒÈ­Çϰí Àü¹ÝÀûÀÎ »ý»ê¼ºÀ» Çâ»ó½ÃŰ°í ¿î¿µ ºñ¿ëÀ» Àý°¨ÇÕ´Ï´Ù. ¹®Á¦¸¦ ³ªÅ¸³¾ ¼ö ÀÖ´Â ¼º´ÉÀÇ ¹Ì¹¦ÇÑ º¯È­¸¦ ½Äº°Çϱâ À§ÇØ AI ½Ã½ºÅÛÀº È÷½ºÅ丮 µ¥ÀÌÅÍ¿Í ¸Ó½Å·¯´× ¾Ë°í¸®ÁòÀ» Ȱ¿ëÇÏ¿© ±â°è¸¦ Áö¼ÓÀûÀ¸·Î ¸ð´ÏÅ͸µÇÕ´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ ¸ðµç ¿ä¼Ò°¡ ½ÃÀå ¼ºÀå¿¡ µµ¿òÀÌ µË´Ï´Ù.

µðÁöÅÐ Àüȯ°ú Ŭ¶ó¿ìµå ±â¼úÀº 4.0 ÇÁ·¹ÀÓ¿öÅ© ÇÏ¿¡¼­ Á¦¾à »ê¾÷À» ÀüÁø½ÃŰ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. À¯¿£Àº µðÁöÅÐ ±â¼úÀÌ ¿ª»ç»ó ¾î´À Çõ½Åº¸´Ù ºü¸¥ ¼Óµµ·Î ¹ßÀüÇϰí ÀÖÀ¸¸ç, ºÒ°ú 20³â ¸¸¿¡ °³¹ßµµ»ó±¹ Àα¸ÀÇ ¾à 50%¿¡ ¿µÇâÀ» ÁÖ¸ç »çȸ¸¦ ±ØÀûÀ¸·Î º¯È­½Ã۰í ÀÖ´Ù°í ¸»ÇÕ´Ï´Ù. µû¶ó¼­ °Ç°­ °ü¸® Àü¹Ý¿¡¼­ µðÁöÅÐ º¯È¯ÀÌ ÁøÇàµÊ¿¡ µû¶ó ½ÃÀå ¼ºÀåÀÌ ÃËÁøµË´Ï´Ù.

½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ

ÀÌ·¯ÇÑ 4.0¿¡¼­´Â ±âÁ¸ Á¦Á¶ ÀÎÇÁ¶óÀÇ ´ë±Ô¸ð Çö´ëÈ­°¡ ÇÊ¿äÇϸç, ÀÌ´Â IoT Áö¿ø ÀåÄ¡, ÀÚµ¿È­ ½Ã½ºÅÛ, ·Îº¿ µî ÃÖ÷´Ü Àåºñ·Î ±¸½Ä ±â°è ±³Ã¼¸¦ Æ÷ÇÔÇÕ´Ï´Ù. ¶ÇÇÑ ±â¾÷Àº ¿¹Ãø ºÐ¼®, ǰÁú °ü¸® ¹× µ¥ÀÌÅÍ ÅëÇÕÀ» °¡´ÉÇÏ°Ô Çϱâ À§ÇØ ÀΰøÁö´É(AI) ¹× ¸Ó½Å·¯´×(ML) Ç÷§Æû°ú °°Àº °í±Þ ¼ÒÇÁÆ®¿þ¾î ¼Ö·ç¼Ç¿¡ ÅõÀÚÇØ¾ß ÇÕ´Ï´Ù. µû¶ó¼­ °í°¡ÀÇ Ãʱâ ÀÚº»°ú Áö¼ÓÀûÀÎ ºñ¿ëÀÇ Á¶ÇÕÀº ÀÌ·¯ÇÑ 4.0 ¼Ö·ç¼ÇÀÇ ±¤¹üÀ§ÇÑ Ã¤¿ë¿¡ Å« Àå¾Ö¹°ÀÌ µÇ¾î ½ÃÀå ÀüüÀÇ ¼ºÀå ±Ëµµ¸¦ µÐÈ­½Ãŵ´Ï´Ù.

À¯Çüº° Àü¸Á

À¯Çü¿¡ µû¶ó ÀÌ ½ÃÀåÀº ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º·Î ³ª´¹´Ï´Ù. ¼­ºñ½º ºÎ¹®Àº 2023³â ÀÌ 4.0 ½ÃÀå¿¡¼­ 45%ÀÇ ¼öÀÍ Á¡À¯À²À» ȹµæÇß½À´Ï´Ù. ÀÌ ºÎ¹®¿¡´Â ±¸Çö, ÄÁ¼³ÆÃ, ±³À°, À¯Áöº¸¼ö µî ´Ù¾çÇÑ Áö¿ø ¼­ºñ½º°¡ Æ÷ÇԵ˴ϴÙ. Á¦¾à ȸ»ç´Â »õ·Î¿î µðÁöÅÐ µµ±¸¿Í ±â¼úÀ» äÅÃÇϱ⠶§¹®¿¡ ÀÌ·¯ÇÑ ½Ã½ºÅÛÀÇ ºÎµå·¯¿î ÅëÇÕ, È¿°úÀûÀÎ »ç¿ë ¹× Àå±â À¯Áö º¸¼ö¸¦ º¸ÀåÇϱâ À§ÇØ Àü¹® ¼­ºñ½º¿¡ ÀÇÁ¸ÇÕ´Ï´Ù.

¿ëµµº° Àü¸Á

¿ëµµº°·Î º¼ ¶§, ÀÌ ½ÃÀåÀº ÀǾàǰ ¹ß°ß ¹× °³¹ß, Á¦Á¶, °ø±Þ¸Á °ü¸® µîÀ¸·Î ºÐ·ùµË´Ï´Ù. °ø±Þ¸Á °ü¸® ºÎ¹®Àº 2023³â ÀÌ 4.0 ½ÃÀå¿¡¼­ 22%ÀÇ ¼öÀÍ Á¡À¯À²À» ȹµæÇß½À´Ï´Ù. ºí·ÏüÀÎ, IoT, °í±Þ ºÐ¼® µîÀÇ µðÁöÅÐ ±â¼úÀ» ÅëÇÕÇÔÀ¸·Î½á ÀǾàǰ °ø±Þ¸Á¿¡ Çõ¸íÀÌ ÀϾ Åõ¸í¼º, º¸¾È, È¿À²¼ºÀÌ Çâ»óµÇ¾ú½À´Ï´Ù.

ÃÖÁ¾ ¿ëµµº° Àü¸Á

ÃÖÁ¾ ¿ëµµ¿¡ µû¶ó ÀÌ ½ÃÀåÀº Á¦¾à ¹× ¹ÙÀÌ¿À ±â¼ú ±â¾÷, ÀÇ·á Á¦°ø¾÷ü, CRO ¹× CDMO·Î ºÐ·ùµË´Ï´Ù. CRO ¹× CDMO ºÎ¹®Àº 2023³â ÀÌ 4.0 ½ÃÀå¿¡¼­ 33%ÀÇ ¼öÀÍ Á¡À¯À²À» ȹµæÇß½À´Ï´Ù. CRO ¹× CDMO´Â ¾Æ¿ô¼Ò½ÌµÈ ¿¬±¸, °³¹ß, Á¦Á¶ ¼­ºñ½º¸¦ Á¦°øÇÔÀ¸·Î½á Á¦¾à±â¾÷°ú ¹ÙÀÌ¿À±â¼ú ±â¾÷À» Áö¿øÇϴµ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

±â¼úº° Àü¸Á

±â¼úÀ» ¹ÙÅÁÀ¸·Î ÀÌ ½ÃÀåÀº AI ¹× ML, ºòµ¥ÀÌÅÍ ¾Ö³Î¸®Æ½½º, IoT, ºí·ÏüÀÎ ±â¼ú µîÀ¸·Î ºÐ·ùµË´Ï´Ù. ºí·ÏüÀÎ ±â¼ú ºÎ¹®Àº 2023³â ÀÌ 4.0 ½ÃÀå¿¡¼­ 9%ÀÇ ¼öÀÍ Á¡À¯À²À» ±â·ÏÇß½À´Ï´Ù. ºí·ÏüÀÎÀº ¾ÈÀüÇϰí Åõ¸íÇÏ¸ç º¯°æ ºÒ°¡´ÉÇÑ ±â·ÏÀ» Á¦°øÇÒ ¼ö Àֱ⠶§¹®¿¡ Á¦¾à ¾÷°è¿¡¼­ ÀǾàǰÀÇ ¾ÈÀü°ú ±ÔÁ¤ Áؼö¸¦ º¸ÀåÇÏ´Â ±ÍÁßÇÑ µµ±¸°¡ µÇ¾ú½À´Ï´Ù.

Áö¿ªº° Àü¸Á

Áö¿ªº°·Î º¸¸é ÀÌ ½ÃÀåÀº ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿, ¾ÆÇÁ¸®Ä«¿¡¼­ ºÐ¼®µÇ°í ÀÖ½À´Ï´Ù. À¯·´ ºÎ¹®Àº 2023³â ÀÌ 4.0 ½ÃÀå¿¡¼­ 29%ÀÇ ¼öÀÍ Á¡À¯À²À» ±â·ÏÇß½À´Ï´Ù. µ¶ÀÏ, ¿µ±¹, ½ºÀ§½º µîÀÇ ±¹°¡µéÀº ÀǾàǰ Á¦Á¶, ±ÔÁ¦ Áؼö, °ø±Þ¸Á °ü¸®ÀÇ È¿À²¼º Çâ»ó¿¡ ÁßÁ¡À» µÎ°í Pharma 4.0 ±â¼úÀ» äÅÃÇÏ´Â µ¥ ÇÙ½ÉÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ½ÃÀå ¹üÀ§ ¹× Á¶»ç ¹æ¹ý

Á¦2Àå ½ÃÀå ¿ä¶÷

Á¦3Àå ½ÃÀå °³¿ä

Á¦4Àå °æÀï ºÐ¼® : ¼¼°è

Á¦5Àå ¼¼°è ½ÃÀå : À¯Çüº°

Á¦6Àå ¼¼°è ½ÃÀå : ¿ëµµº°

Á¦7Àå ¼¼°è ½ÃÀå : ÃÖÁ¾ ¿ëµµº°

Á¦8Àå ¼¼°è ½ÃÀå : ±â¼úº°

Á¦9Àå ¼¼°è ½ÃÀå : Áö¿ªº°

Á¦10Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦11Àå Pharma 4.0 ½ÃÀåÀÇ ¼º°ø Çʼö Á¶°Ç

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global Pharma 4.0 Market size is expected to reach $36.4 billion by 2031, rising at a market growth of 18.5% CAGR during the forecast period.

Telemedicine and remote healthcare solutions have grown significantly in recent years due to the increasing demand for accessible healthcare services. As more patients seek medical consultations and treatments remotely, the pharmaceutical industry must adapt by adopting connected systems that ensure timely drug manufacturing and delivery. According to the World Bank, the global telemedicine industry was expected to grow at an estimated 15% a year before the pandemic by mid-decade. Thus, the Healthcare Providers segment captures $1.8 Billion revenue in 2023.

The major strategies followed by the market participants are Partnerships as the key developmental strategy to keep pace with the changing demands of end users. For instance, In July, 2024, Dassault Systemes SE partnered with Mistral AI, a French AI company, to bring advanced AI, including large language models (LLMs), to industries. This partnership offers LLMaaS through Dassault's secure OUTSCALE infrastructure, empowering customers with AI-powered virtual twin experiences for industrial transformation, sustainability, and innovation, while preserving security and intellectual property. Moreover, In February, 2024, IBM Corporation teamed up with Wipro, an Indian IT company, to launch an Enterprise AI-Ready Platform, leveraging IBM's watsonx AI and data tools to offer clients customizable, integrated AI environments. This new service would enhance AI adoption with improved automation, governance, and flexibility for various industry applications.

COVID 19 Impact Analysis

The pandemic eventually accelerated the adoption of this 4.0 technologies as companies recognized the need for resilient, agile, and efficient manufacturing systems. The pressure to develop and produce COVID-19 vaccines quickly demonstrated the value of AI, automation, and IoT for optimizing production processes. These 4.0 tools, like predictive analytics and remote monitoring, gained widespread attention as pharmaceutical firms sought to minimize disruptions and prepare for future crises. The long-term effect of the pandemic has been a stronger push toward digital transformation in the pharmaceutical industry. Thus, the pandemic had an overall negative impact on the market.

Market Growth Factors

The ability to process vast amounts of data in real-time allows pharmaceutical companies to adopt predictive maintenance strategies, where AI-driven analytics can detect potential equipment failures long before they happen. This capability minimizes downtime, improves overall productivity, and reduces operational costs. In order to identify subtle changes in performance that may indicate a problem, AI systems perpetually monitor machinery by utilizing historical data and machine learning algorithms. Hence, all these factors will aid in the growth of the market.

Digital transformation and cloud technologies are pivotal in advancing the pharmaceutical industry under the 4.0 framework. The United Nations has stated that digital technologies have advanced at a rate that surpasses any innovation in history, affecting approximately 50% of the population of the developing world in a mere two decades and dramatically altering societies. Thus, the increasing digital transformation across healthcare verticals supports the market's growth.

Market Restraining Factors

These 4.0 calls for an extensive modernization of existing manufacturing infrastructure, which includes replacing outdated machinery with cutting-edge equipment, such as IoT-enabled devices, automation systems, and robotics. Additionally, companies must invest in advanced software solutions like artificial intelligence (AI) and machine learning (ML) platforms to enable predictive analytics, quality control, and data integration. Hence, the combination of high upfront capital and ongoing costs creates a significant obstacle to the widespread adoption of these 4.0 solutions, slowing the market's overall growth trajectory.

Type Outlook

Based on type, this market is bifurcated into software and services. The services segment procured 45% revenue share in this 4.0 market in 2023. This segment includes various support services, including implementation, consulting, training, and maintenance. As pharmaceutical companies adopt new digital tools and technologies, they rely on specialized services to ensure smooth integration, effective utilization, and long-term maintenance of these systems.

Application Outlook

By application, this market is divided into drug discovery & development, manufacturing, supply chain management, and others. The supply chain management segment garnered 22% revenue share in this 4.0 market in 2023. Integrating digital technologies, such as blockchain, IoT, and advanced analytics, has revolutionized the pharmaceutical supply chain, providing greater transparency, security, and efficiency.

End Use Outlook

Based on end use, this market is segmented into pharma & biotech companies, healthcare providers, and CRO & CDMO. The CRO & CDMO segment acquired 33% revenue share in this 4.0 market in 2023. The CRO (Contract Research Organizations) & CDMO (Contract Development and Manufacturing Organizations) play a pivotal role in supporting pharmaceutical and biotech companies by offering outsourced research, development, and manufacturing services.

Technology Outlook

On the basis of technology, this market is classified into AI & ML, big data analytics, IoT, blockchain technology, and others. The blockchain technology segment recorded 9% revenue share in this 4.0 market in 2023. Blockchain's ability to provide secure, transparent, and immutable records has made it a valuable tool for ensuring drug safety and compliance in the pharmaceutical industry.

Regional Outlook

Region-wise, this market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The Europe segment witnessed 29% revenue share in this 4.0 market in 2023. Countries like Germany, the United Kingdom, and Switzerland are key players in adopting Pharma 4.0 technologies, focusing on improving the efficiency of drug manufacturing, regulatory compliance, and supply chain management.

Recent Strategies Deployed in the Market

List of Key Companies Profiled

Global Pharma 4.0 Market Report Segmentation

By Type

By Application

By End Use

By Technology

By Geography

Table of Contents

Chapter 1. Market Scope & Methodology

Chapter 2. Market at a Glance

Chapter 3. Market Overview

Chapter 4. Competition Analysis - Global

Chapter 5. Global Pharma 4.0 Market by Type

Chapter 6. Global Pharma 4.0 Market by Application

Chapter 7. Global Pharma 4.0 Market by End Use

Chapter 8. Global Pharma 4.0 Market by Technology

Chapter 9. Global Pharma 4.0 Market by Region

Chapter 10. Company Profiles

Chapter 11. Winning Imperatives for Pharma 4.0 Market

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â